Craft
  • Home
  •  / WuXi AppTec
WuXi AppTec

WuXi AppTec

Scientists and Researchers

32.17 K

FY, 2021

Revenue

¥22.8 B

FY, 2021

Market Capitalization

¥208.3 B

2022-09-20

WuXi AppTec Summary

Company summary

Overview
WuXi AppTec (药明康德, formerly known as WuXi PharmaTech) is a company providing research, development, and manufacturing services to discover and manufacture small molecule drugs and cell and gene therapies. It offers drug discovery, pre-clinical development, and clinical processes research, as well as synthetic chemistry, biology, medicinal chemistry, analytical chemistry, toxicology, bioanalysis, and testing services. The company serves the pharmaceutical, biotech, and medical device industries.
Type
Public
Founded
2000
HQ
Shanghai, CN | view all locations
Website
https://www.wuxiapptec.com/
Cybersecurity rating
ESG rating
out of 100 | View all ESG data
Sectors

Key people

  • Ge Li
  • Minzhang Chen
  • Edward Hu

    Edward Hu, Vice Chairman, Global Chief Investment Officer

  • Shuhui Chen

    Shuhui Chen, Executive Vice President, Chief Scientific Officer, Head of DDSU

    Operating MetricsView all

    Investigational New Drugs Filled

    26
    21.2%

    FY, 2021

    Clinical Trial Authorizations Obtained

    23
    23.3%

    FY, 2021

    DNA Encoded Library Compounds

    90B

    FY, 2021

    LocationsView all

    29 locations detected

    • Shanghai, Shanghai Shi HQ

      China

      288 Fute Middle Rd, Pudong Xinqu

    • Austin, TX

      United States

      5301 Southwest Pkwy #100

    • Cambridge, MA

      United States

      55 Cambridge Pkwy

    • Cranbury Township, NJ

      United States

      6 Cedarbrook Dr

    • Marietta, GA

      United States

      1265 Kennestone Cir

    • Mendota Heights, MN

      United States

      2540 Executive Dr

    and 23 others

    WuXi AppTec Financials

    Summary financials

    Revenue (Q2, 2022)
    ¥9.2B
    Gross profit (Q2, 2022)
    ¥3.4B
    Net income (Q2, 2022)
    ¥3.0B
    Cash (Q2, 2022)
    ¥7.1B
    EBIT (Q2, 2022)
    ¥3.1B
    Enterprise value
    $206.1B

    Footer menu